Complete Filing Data
COGNITION THERAPEUTICS INC reported Stockholders Equity of $34.27 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean COGNITION THERAPEUTICS INC did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income Loss | -$23.5M | -$34.0M | -$25.8M | -$21.4M | -$11.7M | -$7.8M |
| Research And Development Expense | $37.2M | $41.7M | $37.2M | $30.3M | $18.6M | $12.9M |
| Other Nonoperating Income Expense | $24.3M | $20.0M | $24.9M | $22.2M | $16.9M | $9.6M |
| Operating Income Loss | -$47.8M | -$54.0M | -$50.7M | -$43.6M | -$28.6M | -$17.4M |
| Operating Expenses | $47.8M | $54.0M | $50.7M | $43.6M | $28.6M | $17.4M |
| General And Administrative Expense | $10.6M | $12.3M | $13.5M | $13.2M | $10.0M | $4.5M |
| Comprehensive Income Net Of Tax | -$23.5M | -$33.8M | -$25.8M | -$21.4M | -$11.7M | -$7.8M |
| Other Comprehensive Income Loss Net Of Tax | $3.7M | $4.0K | -$1.0K | -$11.0K | -$2.0K | |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $4.0K | -$1.0K | -$11.0K | -$2.0K | ||
| Interest Income Expense Net | -$27.0K | -$28.0K | -$893.0K | -$1.8M | ||
| Interest Income Expense Nonoperating Net | -$13.0K | -$25.0K | -$27.0K | |||
| Net Income Loss Available To Common Stockholders Basic | -$21.4M | -$16.2M | -$12.1M | |||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$4.9M | -$6.7M | -$8.5M | -$9.9M | -$7.0M | -$9.2M | -$6.7M | -$4.7M | -$6.2M | -$6.6M | -$5.8M | -$3.8M | -$3.1M | -$1.5M | $223.0K | -$1.8M | -$1.7M | -$2.5M |
| Research And Development Expense | $3.8M | $11.5M | $10.8M | $11.4M | $11.6M | $10.6M | $11.7M | $8.5M | $5.4M | $8.3M | $9.1M | $6.5M | $3.7M | $4.9M | $4.4M | $3.4M | ||
| Other Nonoperating Income Expense | $1.4M | $7.2M | $5.3M | $4.5M | $7.6M | $5.0M | $8.0M | $7.1M | $2.8M | $6.0M | $6.3M | $5.7M | $2.1M | $4.5M | $5.8M | $2.7M | ||
| Operating Income Loss | -$6.4M | -$14.0M | -$13.8M | -$14.5M | -$14.7M | -$14.1M | -$14.7M | -$11.8M | -$9.0M | -$12.6M | -$12.2M | -$9.4M | -$5.2M | -$6.0M | -$5.6M | -$4.5M | ||
| Operating Expenses | $6.4M | $14.0M | $13.8M | $14.5M | $14.7M | $14.1M | $14.7M | $11.8M | $9.0M | $12.6M | $12.2M | $9.4M | $5.2M | $6.0M | $5.6M | $4.5M | ||
| General And Administrative Expense | $2.6M | $2.5M | $3.0M | $3.1M | $3.1M | $3.5M | $3.1M | $3.3M | $3.5M | $4.4M | $3.1M | $2.9M | $1.5M | $1.1M | $1.2M | $1.1M | ||
| Comprehensive Income Net Of Tax | -$4.9M | -$6.7M | -$8.5M | -$9.9M | -$7.0M | -$9.0M | -$6.7M | -$4.7M | -$6.2M | -$6.6M | -$5.8M | -$3.8M | -$3.1M | -$1.5M | $218.0K | -$1.8M | ||
| Other Comprehensive Income Loss Net Of Tax | -$1.0K | $4.0K | -$1.0K | -$3.0K | $1.0K | -$3.0K | -$1.0K | -$5.0K | $18.0K | $56.0K | -$114.0K | |||||||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $195.0K | -$1.0K | $4.0K | -$1.0K | -$3.0K | $1.0K | -$3.0K | -$1.0K | -$5.0K | $18.0K | ||||||||
| Interest Income Expense Net | -$10.0K | -$2.0K | -$6.0K | -$10.0K | -$2.0K | -$7.0K | -$9.0K | -$357.0K | -$537.0K | -$506.0K | ||||||||
| Interest Income Expense Nonoperating Net | -$3.0K | -$5.0K | -$3.0K | -$7.0K | -$10.0K | -$2.0K | -$6.0K | |||||||||||
| Net Income Loss Available To Common Stockholders Basic | -$6.2M | -$6.6M | -$5.8M | -$3.8M | -$5.0M | -$2.8M | -$905.0K | -$2.9M | ||||||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$4.7M | -$6.2M | -$5.9M | -$3.7M | -$1.5M | $223.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $34.3M | $18.8M | $24.5M | $40.2M | $51.3M | -$68.2M | -$58.4M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $37.0M | $25.0M | $29.9M | $41.6M | $54.7M | $5.2M | $2.9M |
| Cash And Cash Equivalents At Carrying Value | $36.8M | $25.0M | $29.9M | $41.6M | $54.7M | $5.2M | |
| Retained Earnings Accumulated Deficit | -$198.6M | -$175.2M | -$141.2M | -$115.4M | -$94.0M | -$68.2M | |
| Property Plant And Equipment Net | $93.0K | $181.0K | $284.0K | $233.0K | $145.0K | $211.0K | |
| Liabilities Current | $13.9M | $11.1M | $10.2M | $7.8M | $7.9M | $3.3M | |
| Liabilities And Stockholders Equity | $48.4M | $30.2M | $35.2M | $50.4M | $59.1M | $7.1M | |
| Liabilities | $14.1M | $11.5M | $10.7M | $10.2M | $7.9M | $19.9M | |
| Grants Receivable Current | $9.9M | $2.7M | $1.3M | $3.7M | $1.8M | $564.0K | |
| Common Stock Value | $90.0K | $60.0K | $32.0K | $29.0K | $22.0K | $1.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $12.0M | -$4.9M | -$11.6M | -$13.2M | $49.5M | $2.3M | |
| Assets Current | $48.0M | $29.6M | $34.2M | $47.6M | $59.0M | $6.9M | |
| Assets | $48.4M | $30.2M | $35.2M | $50.4M | $59.1M | $7.1M | |
| Accrued Liabilities Current | $12.0M | $7.6M | $4.1M | $2.1M | $1.8M | $994.0K | |
| Accounts Payable Current | $1.1M | $2.0M | $3.7M | $3.2M | $4.2M | $2.0M | |
| Other Liabilities Current | $307.0K | $279.0K | $544.0K | $634.0K | $1.2M | $253.0K | |
| Deferred Grant Income Current | $367.0K | $1.1M | $1.7M | $1.7M | $753.0K | ||
| Repayments Of Short Term Debt | $353.0K | $739.0K | $811.0K | $1.4M | $268.0K | ||
| Operating Lease Right Of Use Asset Amortization Expense | $192.0K | $159.0K | $156.0K | $152.0K | |||
| Operating Lease Right Of Use Asset | $306.0K | $498.0K | $657.0K | $813.0K | |||
| Operating Lease Liability Noncurrent | $195.0K | $342.0K | $520.0K | $695.0K | |||
| Operating Lease Liability Current | $136.0K | $193.0K | $174.0K | $149.0K | |||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$195.0K | -$199.0K | -$198.0K | -$187.0K | |||
| Other Liabilities Noncurrent | $1.7M | $0.00 | |||||
| Preferred Stock Dividends And Other Adjustments | $4.5M | $4.2M | |||||
| Other Assets | $1.7M | ||||||
| Fair Value Adjustment Of Derivative Liability | $2.2M | $18.0K | |||||
| Other Receivables Net Current | $467.0K | $588.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $36.5M | $7.0M | $12.3M | $14.5M | $23.0M | $28.9M | $28.9M | $34.4M | $35.8M | $39.3M | $43.9M | $48.7M | -$86.7M | -$83.7M | -$67.9M | -$66.5M | -$64.5M | -$62.0M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $39.8M | $11.6M | $16.4M | $22.0M | $28.5M | $34.7M | $33.0M | $37.2M | $38.8M | $46.6M | $45.8M | $51.5M | $8.3M | $11.3M | $13.4M | $5.2M | |||
| Cash And Cash Equivalents At Carrying Value | $39.3M | $10.7M | $16.4M | $22.0M | $28.5M | $34.7M | $33.0M | $37.2M | $38.8M | $46.6M | $45.8M | $51.5M | $8.3M | ||||||
| Retained Earnings Accumulated Deficit | -$195.3M | -$190.4M | -$183.6M | -$167.3M | -$157.4M | -$150.3M | -$133.0M | -$126.3M | -$121.6M | -$110.2M | -$103.6M | -$97.8M | -$86.7M | ||||||
| Property Plant And Equipment Net | $159.0K | $174.0K | $190.0K | $207.0K | $234.0K | $257.0K | $281.0K | $248.0K | $253.0K | $246.0K | $245.0K | $261.0K | $141.0K | ||||||
| Liabilities Current | $6.7M | $12.4M | $11.0M | $12.7M | $10.9M | $9.5M | $8.2M | $7.9M | $7.5M | $12.1M | $6.8M | $7.6M | $4.4M | ||||||
| Liabilities And Stockholders Equity | $43.4M | $19.6M | $23.5M | $27.6M | $34.4M | $38.9M | $38.8M | $44.0M | $45.7M | $53.6M | $52.8M | $58.7M | $13.4M | ||||||
| Liabilities | $6.9M | $12.6M | $11.2M | $13.1M | $11.4M | $10.0M | $9.8M | $9.6M | $9.9M | $14.2M | $8.9M | $10.0M | $15.3M | ||||||
| Grants Receivable Current | $1.9M | $6.3M | $4.8M | $3.4M | $3.1M | $861.0K | $1.6M | $2.4M | $1.6M | $2.5M | $3.3M | $2.8M | $847.0K | ||||||
| Common Stock Value | $88.0K | $65.0K | $62.0K | $41.0K | $40.0K | $40.0K | $30.0K | $30.0K | $29.0K | $24.0K | $22.0K | $22.0K | $1.0K | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$8.6M | $4.7M | -$2.8M | -$3.2M | $8.2M | ||||||||||||||
| Assets Current | $42.9M | $19.0M | $22.9M | $26.8M | $33.6M | $38.0M | $36.0M | $41.6M | $42.8M | $50.9M | $50.7M | $56.4M | $10.0M | ||||||
| Assets | $43.4M | $19.6M | $23.5M | $27.6M | $34.4M | $38.9M | $38.8M | $44.0M | $45.7M | $53.6M | $52.8M | $58.7M | $13.4M | ||||||
| Accrued Liabilities Current | $3.9M | $9.4M | $7.7M | $9.5M | $6.1M | $4.7M | $4.3M | $2.4M | $2.1M | $2.3M | $1.7M | $1.4M | $740.0K | ||||||
| Accounts Payable Current | $827.0K | $771.0K | $1.8M | $1.9M | $3.0M | $2.6M | $2.9M | $4.1M | $3.1M | $8.1M | $3.3M | $4.0M | $2.8M | ||||||
| Other Liabilities Current | $41.0K | $161.0K | $185.0K | $366.0K | $2.0K | $217.0K | $427.0K | $402.0K | $799.0K | $913.0K | |||||||||
| Deferred Grant Income Current | $1.7M | $2.0M | $1.1M | $1.1M | $1.5M | $1.6M | $1.7M | $1.1M | $1.6M | $1.6M | $1.3M | $1.3M | |||||||
| Repayments Of Short Term Debt | $118.0K | $178.0K | $207.0K | $394.0K | |||||||||||||||
| Operating Lease Right Of Use Asset Amortization Expense | $54.0K | $31.0K | $39.0K | $38.0K | |||||||||||||||
| Operating Lease Right Of Use Asset | $353.0K | $399.0K | $444.0K | $542.0K | $585.0K | $626.0K | $696.0K | $736.0K | $774.0K | $691.0K | $539.0K | $578.0K | |||||||
| Operating Lease Liability Noncurrent | $212.0K | $229.0K | $280.0K | $392.0K | $440.0K | $488.0K | $565.0K | $608.0K | $651.0K | $603.0K | $404.0K | $446.0K | |||||||
| Operating Lease Liability Current | $168.0K | $198.0K | $194.0K | $188.0K | $184.0K | $180.0K | $170.0K | $166.0K | $157.0K | $114.0K | $161.0K | $150.0K | |||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$196.0K | -$196.0K | -$195.0K | -$201.0K | -$200.0K | -$197.0K | -$196.0K | ||||||||||||
| Other Liabilities Noncurrent | $0.00 | $0.00 | $1.1M | $1.1M | $1.8M | $1.5M | $1.7M | $1.9M | |||||||||||
| Preferred Stock Dividends And Other Adjustments | $1.9M | $1.3M | $1.1M | $1.1M | |||||||||||||||
| Other Assets | $1.8M | $1.4M | $1.8M | $1.7M | $1.3M | $1.4M | |||||||||||||
| Fair Value Adjustment Of Derivative Liability | $1.1M | $1.1M | -$112.0K | ||||||||||||||||
| Other Receivables Net Current | $2.0K | $300.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $2.1M | $3.7M | $4.4M | $3.6M | $5.2M | $475.0K |
| Net Cash Provided By Used In Operating Activities | -$24.6M | -$28.5M | -$16.0M | -$18.5M | -$3.6M | -$3.4M |
| Net Cash Provided By Used In Financing Activities | $36.6M | $23.6M | $4.5M | $5.5M | $53.2M | $5.8M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$1.2M | -$1.6M | -$1.9M | $1.3M | -$21.0K | $417.0K |
| Increase Decrease In Grant Receivables | $7.2M | $1.4M | -$2.4M | $1.9M | $1.2M | -$2.1M |
| Depreciation Depletion And Amortization | $36.0K | $107.0K | $96.0K | $83.0K | $93.0K | $98.0K |
| Increase Decrease In Deferred Grant Income Current | -$699.0K | -$635.0K | -$1.7M | $2.6M | $501.0K | |
| Increase Decrease In Operating Lease Liability | -$204.0K | -$159.0K | -$150.0K | -$121.0K | ||
| Net Cash Provided By Used In Investing Activities | $9.0K | -$4.0K | -$147.0K | -$171.0K | -$27.0K | -$10.0K |
| Payments To Acquire Property Plant And Equipment | $4.0K | $147.0K | $171.0K | $27.0K | $10.0K | |
| Proceeds From Stock Options Exercised | $71.0K | $82.0K | $1.6M | $276.0K | $13.0K | |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $3.5M | $1.9M | $2.4M | -$749.0K | ||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $4.0K | -$1.0K | -$11.0K | -$23.0K | ||
| Increase Decrease In Other Receivables | -$467.0K | -$121.0K | -$904.0K | |||
| Payments Related To Tax Withholding For Share Based Compensation | $164.0K | $128.0K | ||||
| Increase Decrease In Accrued Liabilities | $343.0K | $1.3M | $595.0K | |||
| Increase Decrease In Accounts Payable | -$1.1M | $2.2M | -$364.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|
| Share Based Compensation | $586.0K | $1.2M | $1.2M | $1.0M | $98.0K |
| Net Cash Provided By Used In Operating Activities | -$9.9M | -$7.2M | -$2.7M | -$3.0M | -$772.0K |
| Net Cash Provided By Used In Financing Activities | $1.3M | $12.0M | -$10.0K | -$91.0K | $9.0M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$200.0K | -$583.0K | $72.0K | $1.1M | -$305.0K |
| Increase Decrease In Grant Receivables | $2.1M | -$420.0K | -$2.1M | $995.0K | $1.1M |
| Depreciation Depletion And Amortization | $27.0K | $21.0K | $18.0K | $23.0K | |
| Increase Decrease In Deferred Grant Income Current | -$117.0K | $22.0K | $2.4M | ||
| Increase Decrease In Operating Lease Liability | -$61.0K | -$26.0K | -$36.0K | -$20.0K | |
| Net Cash Provided By Used In Investing Activities | -$41.0K | -$134.0K | |||
| Payments To Acquire Property Plant And Equipment | $41.0K | $134.0K | |||
| Proceeds From Stock Options Exercised | $303.0K | $14.0K | |||
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$75.0K | -$377.0K | -$75.0K | -$539.0K | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $4.0K | $1.0K | |||
| Increase Decrease In Other Receivables | -$467.0K | $63.0K | |||
| Payments Related To Tax Withholding For Share Based Compensation | $46.0K | $106.0K | |||
| Increase Decrease In Accrued Liabilities | -$368.0K | $277.0K | |||
| Increase Decrease In Accounts Payable | -$171.0K | $953.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 72.8M | 39.7M | 30.0M | 23.6M | 5.2M | 508.1K |
| Weighted Average Number Of Diluted Shares Outstanding | 72.8M | 39.7M | 30.0M | 23.6M | 5.2M | 508.1K |
| Earnings Per Share Diluted | $-0.32 | $-0.86 | $-0.86 | $-0.91 | $-3.13 | $-23.76 |
| Earnings Per Share Basic | $-0.32 | $-0.86 | $-0.86 | $-0.91 | $-3.13 | $-23.76 |
| Common Stock Shares Outstanding | 88.9M | 59.9M | 32.2M | 29.0M | 22.2M | 538.8K |
| Common Stock Shares Issued | 88.9M | 59.9M | 32.2M | 29.0M | 22.2M | 538.8K |
| Common Stock Shares Authorized | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 58.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 0.00 |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 78.0M | 63.7M | 61.8M | 40.4M | 40.1M | 33.7M | 30.4M | 29.6M | 29.1M | 23.0M | 22.6M | 22.4M | 611.7K | 593.4K | 550.2K | 537.3K |
| Weighted Average Number Of Diluted Shares Outstanding | 78.0M | 63.7M | 61.8M | 40.4M | 40.1M | 33.7M | 30.4M | 29.6M | 29.1M | 23.0M | 22.6M | 22.4M | 611.7K | 593.4K | 550.2K | 537.3K |
| Earnings Per Share Diluted | $-0.06 | $-0.11 | $-0.14 | $-0.25 | $-0.18 | $-0.27 | $-0.22 | $-0.16 | $-0.21 | $-0.29 | $-0.25 | $-0.17 | $-8.12 | $-4.77 | $-1.64 | $-5.31 |
| Earnings Per Share Basic | $-0.06 | $-0.11 | $-0.14 | $-0.25 | $-0.18 | $-0.27 | $-0.22 | $-0.16 | $-0.21 | $-0.29 | $-0.25 | $-0.17 | $-8.12 | $-4.77 | $-1.64 | $-5.31 |
| Common Stock Shares Outstanding | 88.3M | 65.0M | 62.0M | 40.8M | 40.1M | 40.0M | 30.4M | 30.3M | 29.3M | 24.0M | 22.6M | 22.6M | 615.9K | |||
| Common Stock Shares Issued | 88.3M | 65.0M | 62.0M | 40.8M | 40.1M | 40.0M | 30.4M | 30.3M | 29.3M | 24.0M | 22.6M | 22.6M | 615.9K | |||
| Common Stock Shares Authorized | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 70.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | ||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.1M | $82.0K | $4.4M | $3.6M | $5.2M | $475.0K |
| Other Noncash Income Expense | $919.0K | $666.0K | $158.0K | -$35.0K | -$88.0K | $394.0K |
| Grant Income | $23.4M | $19.5M | $24.8M | $22.2M | $17.4M | $10.9M |
| Stock Issued During Period Shares Stock Options Exercised | 50.4K | 93.3K | 0.00 | 1.8M | 321.7K | 18.5K |
| Prepaid Expense Current | $1.1M | $1.9M | $3.0M | $2.4M | $2.0M | $544.0K |
| Additional Paid In Capital | $232.8M | $193.9M | $165.8M | $155.8M | $145.5M | $222.0K |
| Stock Issued During Period Value Stock Options Exercised | $71.0K | $82.0K | $1.6M | $276.0K | $13.0K | |
| Stock Issued During Period Value Vesting Of Restricted Stock Units | -$166.0K | -$128.0K | ||||
| Prepayment Of Insurance Through Third Party Financing | $381.0K | $475.0K | $721.0K | $838.0K | $1.2M | |
| Amortization Of Financing Costs | $31.0K | $54.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $522.0K | $621.0K | $586.0K | $896.0K | $1.1M | $1.2M | $1.1M | $1.0M | $1.2M | $777.0K | $892.0K | $1.0M | $72.0K | $94.0K | $98.0K | $129.0K | $88.0K | $125.0K |
| Other Noncash Income Expense | $230.0K | $141.0K | $214.0K | $236.0K | $333.0K | $244.0K | $314.0K | $172.0K | -$615.0K | $55.0K | -$42.0K | -$195.0K | $8.0K | $103.0K | $145.0K | $95.0K | ||
| Grant Income | $1.2M | $7.1M | $5.1M | $4.3M | $7.3M | $4.9M | $7.7M | $6.9M | $3.4M | $5.9M | $6.4M | $5.9M | $3.0M | $4.6M | $4.7M | $3.2M | ||
| Stock Issued During Period Shares Stock Options Exercised | 44.2K | 20.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.4M | 19.3K | 348.6K | 5.0K | 0.00 | 20.8K | |||||
| Prepaid Expense Current | $1.2M | $1.2M | $1.7M | $1.5M | $1.9M | $2.4M | $1.4M | $2.0M | $2.4M | $1.8M | $1.7M | $2.1M | $571.0K | |||||
| Additional Paid In Capital | $231.7M | $197.3M | $195.8M | $181.8M | $180.4M | $179.2M | $162.1M | $160.9M | $157.5M | $149.7M | $147.7M | $146.8M | $142.0K | |||||
| Stock Issued During Period Value Stock Options Exercised | $65.0K | $17.0K | $65.0K | $1.3M | $22.0K | $303.0K | $5.0K | $34.0K | $14.0K | $11.0K | ||||||||
| Stock Issued During Period Value Vesting Of Restricted Stock Units | -$36.0K | -$5.0K | -$46.0K | -$22.0K | -$106.0K | |||||||||||||
| Prepayment Of Insurance Through Third Party Financing | ||||||||||||||||||
| Amortization Of Financing Costs | $22.0K | $18.0K |
Most recent annual filing with the SEC: March 26, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.